Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.69 |
| ▸ | NPC1 | O15118 | 4/20 | 0.69 |
| ▸ | RAB9A | P51151 | 4/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.62 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14736626 | 0.98 | MAPT (0.74) | MAPTSMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL5114083 | 0.90 | MAPT (0.88) | MAPTSMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL8088128 | 0.88 | MAPT (0.97) | MAPTSMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL230079 | 0.87 | MAPT (1.00) | MAPTSMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL14050118 | 0.85 | MAPT (0.76) | MAPTSMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL2929122 | 0.85 | MAPT (0.66) | MAPTSMN1; SMN2NPC1RAB9AGAA | |
| Hydrochloric Acid SCHEMBL5008245 | 0.84 | MAPT (0.64) | MAPTSMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL3640134 | 0.84 | LMNA (0.64) | MAPTSMN1; SMN2NPC1RAB9AGAA | |
| Hydrochloric Acid SCHEMBL5206474 | 0.84 | MAPT (0.64) | MAPTSMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL29858847 | 0.82 | NPC1 (1.00) | MAPTSMN1; SMN2NPC1RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772510-B2 | PDE10 modulators | HOFFMANN-LA ROCHE INC. (US) | 2014-07-08 | — | — | US | claimed |
| US-20130059833-A1 | PDE10 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | US | claimed |
| US-20160244464-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2016-08-25 | — | — | US | disclosed |
| US-20160031907-A1 | Substituted Benzene Compounds | Epizyme, Inc. | 2016-02-04 | — | — | US | disclosed |
| US-9243001-B2 | Substituted benzene compounds | Epizyme, Inc. (US) | 2016-01-26 | — | — | US | disclosed |
| EP-2970281-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2753604-B1 | PDE10 MODULATORS | HOFFMANN LA ROCHE (CH) | 2015-08-19 | — | — | EP | disclosed |
| WO-2014172044-A1 | SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2014-10-23 | — | — | WO | disclosed |
| US-20140315945-A1 | Substituted Benzene Compounds | Epizyme, Inc. (US) | 2014-10-23 | — | — | US | disclosed |
| US-8772510-B2 | PDE10 modulators | HOFFMANN-LA ROCHE INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8563714-B2 | Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-10-22 | — | — | US | disclosed |
| EP-2574607-A1 | PDE10 modulators | F. Hoffmann-La Roche AG (CH) | 2013-04-03 | — | — | EP | disclosed |
| WO-2013034506-A1 | PDE10 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-14 | — | — | WO | disclosed |
| US-20130059833-A1 | PDE10 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | US | disclosed |
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-10 | — | — | US | disclosed |
| EP-2432760-A1 | BRIDGED SPIRO [2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-03-28 | — | — | EP | disclosed |
| US-20120028975-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND ANALOGS THEREOF | SCHERING CORPORATION | 2012-02-02 | — | — | US | disclosed |
| WO-2010134014-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-25 | — | — | WO | disclosed |
| US-7625919-B2 | 4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625919-B2 | 4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | FPR1, FPR2, FPR3 | MAPT 4373/4885SMN1; SMN2 3806/4885NPC1 3287/4885 |
| US-20160031907-A1 | Substituted Benzene Compounds | CYP1B1, CYP4B1, CYP2B6 | MAPT 4438/4885SMN1; SMN2 2439/4885NPC1 841/4885 |
| US-20130059833-A1 | PDE10 MODULATORS | PDE10A, PDE5A, PDE2A | MAPT 1196/4885SMN1; SMN2 1133/4885NPC1 2474/4885 |
| US-20120028975-A1 | SUBSTITUTED TRIAZOLOPYRIDINES AND ANALOGS THEREOF | PDE2A, PDE5A, PDE4A | MAPT 3107/4885SMN1; SMN2 1754/4885NPC1 3163/4885 |
| US-20140315945-A1 | Substituted Benzene Compounds | VHL, AHR, TP53 | MAPT 3772/4885SMN1; SMN2 3878/4885NPC1 1399/4885 |
| US-20160244464-A1 | SUBSTITUTED BENZENE COMPOUNDS | VHL, AHR, TP53 | MAPT 3772/4885SMN1; SMN2 3878/4885NPC1 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.